Summary:
To evaluate the clinical significance of a cytomegalovirus (CMV) antigenemia assay in the prediction and diagnosis of CMV gastrointestinal (CMV-GI) disease after hematopoietic stem cell transplantation (HSCT), 19 allogeneic HSCT recipients developing CMV-GI disease were retrospectively reviewed. All patients were monitored by a CMV antigenemia assay, at least once weekly after engraftment. The median onset of CMV-GI disease occurred 31 days post transplant (range: 19-62). Only four of 19 patients (21%) developed a positive CMV antigenemia test before developing CMV-GI diseases. Although all 19 patients subsequently developed positive CMV antigenemia tests during their clinical courses, the values remained at a low-level in nine (47%) patients. Among the 14 patients in whom results of real-time polymerase chain reaction (PCR) were available, seven (50%) yielded positive results of real-time PCR before developing CMV-GI disease. In contrast to the values of CMV antigenemia, all 14 patients exclusively yielded high viral loads (median: 2.8 Â 10 4 copies/ml plasma). We conclude that CMV antigenemia testing has limited value in prediction or early diagnosis of CMV-GI disease, and that real-time PCR could have a more diagnostic significance. Cytomegalovirus (CMV) disease remains a serious infectious complication that causes morbidity and mortality in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). 1 Although the incidence of CMV disease has decreased over time, prophylactic therapy (the administration of antiviral agents to all HSCT recipients), largely due to its toxicities, resulted in no survival benefit. [2] [3] [4] Subsequently, many investigators focused on pre-emptive therapy, treating only patients with proven CMV infection or reactivation. [4] [5] [6] [7] [8] Rapid, sensitive, quantitative, and reliable methods, which can detect CMV reactivation before CMV disease develops, are essential for the refinement of pre-emptive therapy. The CMV antigenemia assay is one of the most widely used methods to detect CMV reactivation in a variety of clinical settings, 9,10 and CMV antigenemia-based pre-emptive therapy has been shown to effectively prevent the occurrence of CMV pneumonitis. 4, 7, 8 However, several reports, including ours, have suggested that pre-emptive therapy based on CMV antigenemia allowed the development of CMV diseases other than pneumonitis, including gastrointestinal (GI) disease, retinitis, and hepatitis, in a small number of patients. 4, 7, 8 In the present study, we focused on CMV-GI disease in allogeneic HSCT recipients, and evaluated the predictive and diagnostic values of the CMV antigenemia assay in CMV-GI disease in comparison with the efficacy of quantitative real-time polymerase chain reaction (PCR).
Patients and methods

Patients and transplant procedures
Among the recipients of allogeneic bone marrow or peripheral blood stem cells at five transplant centers, those who developed histologically diagnosed CMV-GI disease were enrolled into this study. Clinical data from each patient were collected from the medical records and reviewed retrospectively.
CMV antigenemia assay
All patients enrolled into this study were monitored at least once a week for CMV reactivation with a CMV antigenemia assay after engraftment. CMV antigenemia assay using the monoclonal antibodies C10/C11 (Biotest, Dreieich, Germany) or HRP-C7 (Teijin, Tokyo, Japan) was performed as previously reported. [7] [8] [9] [10] High-level CMV antigenemia was defined as 10 or more positive cells per applied 150 000 granulocytes for C10/11, and 10 or more positive cells per 50 000 granulocytes for HRP-C7.
Real-time PCR
Real-time PCR was performed basically as previously reported. 11,12. In brief, DNA extracted from 100 ml of plasma, using a QIAamp Blood Mini Kit (QIAGEN, Valencia, CA, USA), was subjected to PCR. The sequences of PCR primers and the probe were selected from the US17 region of CMV AD169. The Taqman probe selected between the primers was dual-labeled with 6-carboxyfluorescein (FAM) and with 6-carboxy-teremethyl-rhodamine (TAMRA). PCR reaction was performed by using TaqMan Universal PCR Master Mix (PE Biosystems, Foster City, CA, USA). CMV quantification was carried out with a serially diluted standard ranging from 10 to 1 Â 10 7 copies/ well, and the gene copy numbers were calculated by Sequence Detection System ver.1.6.3. software (PE Biosystems). The minimum detection level was 20 copies/100ml of plasma. A high-level copy number was defined as 1000 or more copies of CMV-DNA per ml of plasma.
Definition of CMV-GI disease
CMV-GI disease was defined as gastrointestinal symptoms such as diarrhea, nausea, and epigastralgia, accompanied by histologic demonstration of CMV on biopsy materials obtained by endoscopy.
Results
Study population
Nineteen patients with histologically diagnosed CMV-GI disease were collected, and then subjected to retrospective review. Patient characteristics are shown in Table 1 . Except for one case of aplastic anemia, all these patients had undergone allogeneic HSCT for the treatment of hematological malignancies. Conditioning regimens included total body irradiation (TBI)-based regimens (n ¼ 13), busulfanbased regimens (n ¼ 3), a fludarabine-based regimen (n ¼ 2), and total lymphoid irradiation plus cyclophosphamide (n ¼ 1). A total of 10 patients received a transplant from an unrelated donor. All but one patient developed acute graft-versus-host disease (GVHD) of grade II-IV, and received high-dose glucocorticoids in addition to the ongoing cyclosporin A or tacrolimus. No patient developed CMV disease in any organs outside the gastrointestinal tract.
Onset of CMV-GI disease and CMV antigenemia/real-time PCR
The median onset of CMV-GI disease was 31 days post transplant (range: days 19-62). Only four (21%) of the 19 patients yielded positive CMV antigenemia test before developing CMV-GI disease. Although these four patients were pre-emptively treated with ganciclovir, they subsequently developed CMV-GI disease. The remaining 15 patients developed CMV-GI disease before CMV antigenemia was identified, and were therapeutically treated with ganciclovir. Of these patients, however, all became CMV antigenemia positive after the diagnosis of CMV-GI disease. Among the 14 patients with evaluable real-time PCR results, seven (50%) yielded positive results before the development of CMV-GI disease. As well as positivity for CMV antigenemia, the remaining seven patients yielded positive real-time PCR results after the diagnosis of CMV-GI disease.
Quantitative significance of CMV antigenemia/real-time PCR in CMV-GI disease
The quantitative significance of CMV antigenemia and real-time PCR in association with CMV-GI disease was evaluated by the maximum values of each assay ( Table 2) . The values of CMV antigenemia remained at low levels in nine (47%) of the 19 patients, whereas maximum viral load evaluated by real-time PCR was high in all patients.
Discussion
The introduction of the CMV antigenemia assay, a sensitive and quantitative assay to detect viral reactivation, has contributed to the successful outcome of preemptive therapy for CMV disease in allogeneic HSCT recipients. However, we and other investigators have pointed out that the assay has some disadvantages. 7, 12, 13 For example, it is relatively time-consuming, involves subjective components in the interpretation of slides, and requires sufficient granulocytes. Furthermore, despite its high sensitivity in detecting viral reactivation before the onset of CMV pneumonitis, CMV antigenemia does not necessarily precede the onset of other CMV diseases; thus CMV-GI disease or CMV retinitis can occur in allogeneic HSCT recipients receiving CMV antigenemia-guided pre-emptive therapy. [4] [5] [6] [7] In this retrospective study, we evaluated the clinical significance of CMV antigenemia in predicting and diagnosing CMV-GI disease in allogeneic HSCT recipients. Among 19 cases of histologically diagnosed CMV-GI disease, CMV antigenemia preceded the onset of disease in only four (21%) patients, although the remaining patients subsequently became CMV antigenemia positive after developing CMV-GI disease. These findings strongly suggested that CMV antigenemia is of little clinical value in predicting and diagnosing CMV-GI disease. In addition, these four patients developed CMV-GI disease after starting pre-emptive therapy, suggesting that CMV antigenemia can confirm viral reactivation before CMV-GI disease develops in some cases, but not early enough for therapy to be preventive.
In addition to the CMV antigenemia assay, PCR is a useful technique for detecting CMV reactivation. 13, 14 There have been several reports of using PCR for pre-emptive therapy in allogeneic HSCT recipients. [15] [16] [17] Although it has been reported that PCR is highly sensitive in the detection of viral reactivation and that PCR-guided pre-emptive therapy is effective in preventing the development of CMV diseases, conventional PCR, as compared to the CMV antigenemia assay, is of less clinical use because of lack of quantification. The quantitative real-time PCR is in clinical use, and has become recognized as one of the standard assays for evaluating viral reactivation both qualitatively and quantitatively. 12, 13 In this study, we investigated the clinical significance of real-time PCR and that of the CMV antigenemia assay in assessing viral reactivation in cases of CMV-GI disease. Comparatively, PCR was more effective in predicting and diagnosing CMV-GI disease, although its incidence of preceding disease onset was only 50%. Thus, even real-time PCR, which is considered more sensitive than the CMV antigenemia assay, could not satisfactorily detect CMV reactivation before the onset of CMV-GI Table 2 CMV-GI disease and the results of CMV antigenemia/real-time PCR disease. This result strongly suggested that real-time PCRguided pre-emptive therapy could not completely prevent the occurrence of CMV-GI disease. However, it is possible that the incidence of CMV-GI disease might be lower in patients receiving real-time PCR-guided pre-emptive therapy than in those receiving CMV antigenemia-guided preemptive therapy, simply due to the higher sensitivity of real-time PCR. We conclude that, in the setting of allogeneic HSCT, the occurrence of CMV-GI disease is uniformly observed at a particular frequency even in patients receiving strict CMV surveillance and pre-emptive therapy using the CMV antigenemia assay or PCR, and consider that the latter may be more useful. Consequently, the results of these assays should not be wholly relied on in the diagnosis and prediction of CMV-GI disease. Further modification of CMV antigenemia-guided pre-emptive therapy should focus on using more sensitive PCR methods, and take into consideration individual patient CMV-specific immune reconstitution.
